Taysha Gene Therapies Cash Flow Statement (2019-2026) | TSHA

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Operating Activities
Net Income (Quarter)	-40.93M	-51.19M	-50.39M	-50.31M	-34.09M	-26.53M	-55.07M	-17.61M	-24.60M	-16.61M	-15.04M	-22.67M	-19.89M	-23.82M	-18.25M	-20.11M	-24.91M	-30.87M	-25.44M	-40.91M
Depreciation and Depletion (Quarter)	0.10M	0.20M	0.22M	0.30M	0.30M	0.30M	0.40M	0.30M	0.40M	0.30M	0.40M	0.30M	0.30M	0.30M	0.26M	0.28M	0.30M	0.20M	0.30M	0.29M
Share-based Compensation (Quarter)	4.55M	5.09M	4.96M	5.33M	4.14M	4.47M	4.10M	1.68M	2.22M	2.04M	1.97M	3.20M	3.33M	3.36M	3.22M	3.29M	3.19M	3.29M	3.53M	5.55M
Gains from Sales and Divestitures (Quarter)	0.63M	0.36M	0.43M	0.06M	0.13M	0.19M	0.63M	0.06M	0.03M	0.03M	0.56M	0.02M	0.24M	0.32M	0.32M	1.05M	1.05M	1.25M	1.25M	1.78M
Gains from Investment Securities (Quarter)	0.96M	0.16M	0.06M	1.90M	5.15M	1.68M	-0.29M	0.25M	2.41M	2.57M	-65.96M	0.34M	3.40M	2.51M	-0.08M	-0.01M	3.46M	9.50M	-0.76M	4.46M
Asset Writedowns and Impairment (Quarter)										0.62M	0.45M			4.84M
Non-cash Items (Quarter)	0.79M	47.30M	44.70M	47.40M	0.09M	29.20M	0.06M	12.60M	10.90M	9.30M	1.96M	14.29M	6.87M	1.00M	1.97M	22.20M	0.50M	0.30M	81.68M	0.20M
Cash from Operations (Quarter)	-22.82M	-31.93M	-40.26M	-40.94M	-33.35M	-28.81M	14.71M	-20.18M	-18.77M	-17.95M	-16.12M	-19.80M	-21.50M	-21.61M	-18.31M	-22.02M	-20.18M	-24.17M	-26.72M	-40.88M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)				0.31M	0.34M	0.39M	0.28M	0.30M	0.30M	0.30M	0.27M	0.33M	0.29M	0.30M	0.30M	0.34M	0.31M	0.31M	0.40M	0.28M
Depreciation & Amortization (CF) (Quarter)	0.10M	0.20M	0.22M	0.30M	0.30M	0.30M	0.40M	0.30M	0.40M	0.30M	0.40M	0.30M	0.30M	0.30M	0.26M	0.28M	0.30M	0.20M	0.30M	0.29M
Change in Working Capital
Change in Account Payables (Quarter)	0.51M	13.62M	-16.01M	2.54M	3.67M	-9.43M	-4.59M	0.36M	1.76M	-3.19M	-1.23M	3.98M	-1.61M	-3.78M	-1.50M	0.92M	3.00M	-1.95M	-2.13M	1.29M
Change in Accured Expenses (Quarter)	11.87M	-2.87M	5.36M	-0.78M	-7.68M	-0.12M	-0.75M	-0.25M	-1.07M	-2.94M	-2.02M	0.42M	-2.38M	0.43M	0.11M	-2.12M	0.73M	5.01M	2.67M	-5.15M
Investing Activities
Capital Expenditures (Quarter)	3.00M	3.50M	-6.89M	0.02M	16.27M	2.02M	2.31M	3.90M	-0.05M	-3.43M	3.45M	0.14M	0.30M	-0.07M	-0.33M	0.38M	0.03M	-0.39M	0.71M	0.02M
Cash from Investing Activities (Quarter)	-8.50M	-4.00M	-8.52M	-11.43M	-8.11M	-3.02M	-2.37M	-3.90M	0.05M	-3.49M	-0.01M	-0.14M	-0.20M	-0.04M	0.01M	-0.37M	0.06M	-0.05M	-0.25M	-3.02M
Financing Activities
Other financing activities (Quarter)				-0.23M	-0.53M	0.06M	1.07M	0.39M	-0.54M	-0.10M	0.02M	-0.03M	0.05M	-0.23M	0.23M	-0.08M	0.12M	-0.28M	-0.09M	0.02M
Debt Issuance and Repayment
Long-Term Debt Issuances (Quarter)			10.00M
Change in Capital Stock
Shares Issued (Quarter)				0.28M	-11.28M	11.32M	-11.39M	0.05M		0.45M		0.03M		0.06M		0.07M		0.08M	1.06M	0.52M
Preferred Shares Issued (Quarter)
Misc.
Cash from Financing Activities (Quarter)			9.11M	-0.11M	11.07M	-0.10M	41.23M	-0.37M	0.38M	140.63M	-4.25M	-0.02M	70.47M	6.59M	-0.36M	-0.05M	216.29M	8.80M	49.56M	0.71M
Change in Cash (Quarter)	-31.31M	-5.96M	-39.67M	-52.47M	-30.39M	-31.93M	53.57M	-24.45M	-18.34M	119.19M	-20.38M	-19.96M	48.76M	-15.05M	-18.65M	-22.44M	196.17M	-15.42M	22.59M	-43.19M
Beginning Cash Balance (Quarter)
Free Cash Flow (Quarter)	-25.81M	-35.44M	-33.37M	-40.96M	-49.62M	-30.83M	12.40M	-24.09M	-18.72M	-14.52M	-19.56M	-19.94M	-21.81M	-21.55M	-17.98M	-22.40M	-20.21M	-23.78M	-27.43M	-40.90M
Net Cash Flow (Quarter)	-31.31M	-35.94M	-39.67M	-52.47M	-30.39M	-31.93M	53.57M	-24.45M	-18.34M	119.19M	-20.38M	-19.96M	48.76M	-15.05M	-18.65M	-22.44M	196.17M	-15.42M	22.59M	-43.19M

Research Tools

Developers

Taysha Gene Therapies Cash Flow Statement (2019-2026) | TSHA

Research Tools

Developers

Taysha Gene Therapies Cash Flow Statement (2019-2026) | TSHA

Create an account

Sign In

Reset Password